VNRX · Categories · Leadership
VNRX - Leadership updates
VolitionRX Limited (VNRX) leadership updates - real-time wire coverage filtered to Leadership only.
Recent Leadership for VNRX
- Volition Announces the Appointment of New Distributor for Nu.Q® DiscoverHENDERSON, Nev., Feb. 10, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces the appointment of Medical & Biological Laboratories Co. Ltd (MBL) as a non-exclusive distributor of its Nu.Q® Discover assays in Japan. Dr Jasmine Kway, Chief Executive Officer, Singapore Volition commented: "We are delighted to be working with MBL, a leading provider of clinical research tools in Japan, with a particular focus and track record in autoimmune diseases. "Through our Nu.Q® Discover pillar, we are now serving close to 100 clients worldwide, including many top pharma and diagnostic companies, accelerating disease research and drug developme
- Volition Continues to Extend Access to Nu.Q® Vet Cancer TestHENDERSON, Nev., Jan. 20, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces the appointment of two new centralized laboratory providers of its Nu.Q® Vet Cancer test in the U.S. and Asia, further expanding access to its canine cancer early detection tool. Midwest Veterinary Laboratory, a full-service independent reference laboratory in the U.S., will be offering the Nu.Q® Vet Cancer test to its customers across all 50 states from February 2026.Bioguard, a global animal health diagnostics company is now offering the Nu.Q® Vet Cancer Test through it's Animal Health Diagnostic Center, the first certified ISO/IEC 17025 animal diseas
- Volition Issues Business Review 2024HENDERSON, Nev., Jan. 8, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, has issued a Business Review of 2024, outlining its key highlights from the past year. Volition's major achievements in 2024 include: Expanded access to the Nu.Q® Vet Cancer Test – now available for purchase in 20 countries worldwide.Sold over 110,000 Nu.Q® Vet Cancer Tests in the first three quarters 2024.Hosted Satellite Symposium at European Society of Intensive Care Medicine 2024 showcasing Nu.Q® NETs clinical utility in over 3,000 intensive care sepsis patients.Continued to strengthen our strategic patent portfolio.Made significant progress a
- Volition Appoints Timothy I. Still as ChairmanHENDERSON, Nev., Nov. 6, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, has appointed Timothy Still as Chairman of its board of directors, effective November 06, 2024. Mr. Still is currently Chairman and CEO of TSTILL Enterprises LLC, and an Operating Partner with REVIVAL Healthcare. An accomplished executive with a career spanning over 35 years in medical diagnostics, devices and digital health, his background includes extensive experience in designing and implementing highly focused commercial and business development
- Volition Appoints Dr. Ethel Rubin as an Independent DirectorHENDERSON, Nev., Sept. 30, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, has appointed Dr. Ethel Rubin to its board of directors, as an independent director, effective September 30, 2024. Dr. Rubin has also been appointed as a member of the Audit Committee and the Compensation Committee. Dr. Rubin has over 20 years' experience within the life sciences sector, leading healthcare innovation and commercialization strategies for a wide range of organizations – from early-stage operations to large global corporate businesses
- Volition appoints PharmaVentures for Capture PCR™ and oncology portfolio licensingHENDERSON, Nev., July 9, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, has appointed PharmaVentures Ltd ("PharmaVentures"), a leading transaction advisory firm, to provide strategic advice and transactional support on the out-license of Volition's expanding oncology portfolio. PharmaVentures has been engaged to act as an advisor to Volition to help secure licensing deals with industry leaders for both Nu.Q® Cancer – a range of simple blood-based assays to help detect, guide treatment, and monitor cancer, and Capture-PCR™ – a novel detection method for liquid biopsy in cancer and potentially other diseases. Gael Forterre, Chief Commer
- Volition appoints Dr Andrew Retter as Chief Medical OfficerHENDERSON, Nev., March 19, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, has appointed Dr Andrew Retter as its Chief Medical Officer, effective April 1, 2024. Dr Retter will provide medical leadership at Volition and ensure the company's scientific and clinical efforts are aligned with patient needs. Andrew is an Intensive Care Consultant at Guy's and St. Thomas' NHS Foundation Trust in London, where he has worked as a Consultant since 2014 and leads Clinical Governance in Critical Care. He specializes in the management
- Volition Appoints Mickie Henshall as an Independent DirectorHENDERSON, Nev., Aug. 16, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE: VNRX) ("Volition"), a multi-national epigenetics company, has announced the appointment of Mickie Henshall to its board of directors effective August 15, 2022. Ms. Henshall was also appointed as a member of the Compensation Committee and the Nominations and Governance Committee. Mickie is a seasoned marketing executive with over 20 years of experience in developing and implementing marketing and sales strategies within the IVD, clinical, and life science industries. Early on in her career, Ms. Henshall s
- Volition Appoints DXOCRO to Spearhead U.S. FDA StrategyHENDERSON, Nev., Aug. 8, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, has appointed Diagnostic Oncology CRO, LLC ("DXOCRO") to undertake development and clinical validation studies for its Nu.Q® product portfolio in the United States. DXOCRO will conduct large-scale finding studies across multiple sites in the U.S. using Volition's Nu.Q® NETs and Nu.Q® Cancer tests to determine clinical utility in sepsis and cancer. Volition anticipates that subsequent studies will investigate the chosen intended use claims of the tests, with the objective to gain clearance, authorization, or approval from the United States Food and Drug Administrati
- Volition appoints Sharon Ballesteros as U.S. Head of Quality and Development ProcessAUSTIN, Texas, April 6, 2022 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, has announced the appointment of Sharon Ballesteros as U.S Head of Quality and Development Process. Sharon has over 20 years of experience within the in vitro diagnostics industry with senior program management, quality assurance, and process improvement roles at Siemens Health Diagnostics, Thermo Fisher, and Agena Bioscience. Most recently, Sharon was Director of Design Quality and Risk at GRAIL where she led the company's Design Controls and Risk programs. Sharon joins Volition America, Volition's wholly owned U.S. subsidiary, as the company expands its team and o
- VolitionRx Limited Appoints Dr. Tom Butera DVM as Chief Executive Officer for Volition Veterinary SubsidiaryAUSTIN, Texas, March 30, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, announced today the appointment, effective May 1, 2021, of Dr. Tom Butera DVM, to the position of Chief Executive Officer, Volition Veterinary Diagnostics Development LLC, assuming such role from Dr. Gaetan Michel who continues to serve as Chief Operating Officer of Volition and Chief Executive Officer of Belgian Volition. "We are delighted that Tom has agreed to lead our Veterinary subsidiary. Tom is a proven entrep
- VolitionRx Limited Appoints Two New DirectorsAUSTIN, Texas, March 29, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, announced today the appointment of Ms. Kim Nguyen and Mr. Richard Brudnick to the Company's Board of Directors effective March 25, 2021. Ms. Nguyen was also appointed as Chair of the Company's Compensation Committee and as a member of the Nominations and Governance Committee, and Mr. Brudnick was appointed as a member of the Company's Audit Committee and Compensation Committee. "We are pleased to welcome Kim and Ric
- VolitionRx Provides a Business Update and Appoints Key Officers to Drive Commercialization EffortsAUSTIN, Texas, Feb. 2, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today provided a business update and announced the appointment of a new Chief Financial Officer, Mr. Terig Hughes, in addition to the appointment of Dr. Gaetan Michel as Chief Operating Officer, Mr. Gael Forterre as Chief Commercial Officer, and Dr. Mark Eccleston as Chief Technology Officer. A video providing a business update and introducing Volition’s new team members. "Despite the pandemic we achieved a lot throughout 2020 and the momentum has continued into 2021 with a very busy January. We have opened our new manufacturing facility "Silver One", announced additional
- VolitionRx Limited Awarded an Additional $4 Million in Non-Dilutive FundingAUSTIN, Texas, Jan. 6, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it has been awarded additional non-dilutive funding totaling approximately $4 million from the Walloon Region and Namur Invest, Belgium. To date, Agencies from the Walloon Region have awarded Volition an aggregate of approximately $13 million in non-dilutive funding including this most recent award. This additional funding consisted of a cash grant of $1.3 million and $2.7 million in loans. "It is a key part of our financing strategy to actively seek non-dilutive funding as this provides additional cash at favorable terms to support the Company's continued development, and th